alexa Binding Of The Methyl Donor SAM To MERS-CoV 2'-O-methyltransferase Nsp16 Promotes The Recruitment Of The Allosteric Activator Nsp10
ISSN: 2161-0517

Virology & Mycology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

9th International Virology Congress and Expo
March 13-14, 2017 London, UK

Wahiba Aouadi
Aix-Marseille University, France
Posters & Accepted Abstracts: Virol Mycol
DOI: 10.4172/2161-0517.C1.018
The Middle East respiratory syndrome coronavirus (MERS-CoV), causing severe pneumonia and renal failure in humans, appeared in the Middle East with secondary spread to Europe, Africa, Asia and North America since 2012. The World Health Organization reported 1618 cases with high case-fatality rate around 36%. The fatal outcome of MERS-CoV is caused by a poorly coordinated innate immune response with ineffective activation of the adaptive immune response that failed to clear MERS-CoV viremia from the host. The 5’ end of coronaviruses positive stranded genome is decorated by a cap-1 structure (7mGpppN2’Om). The MERS-CoV encodes for two putative SAM-dependent methyltransferases, non-structural proteins (nsp) nsp14 and nsp16, supposed to methylate cap structure at the N7 position of the guanosine and at the 2-oxygen of the first nucleotide (N1) ribose, respectively. These cap modifications are essential for virus replication. The N7-methylation promotes RNA translation into viral proteins and the 2’-O methylation prevents virus detection by cell innate immunity mechanisms and viral translation inhibition by the interferonstimulated IFIT-1 protein. In this work, we demonstrate that nsp14 is an N7-methyltransferase (MTase) converting GpppG-RNA into a cap-0 structure (7mGpppG-RNA). These cap-0 RNAs are next methylated at the 2’O position of the first RNA nucleotide by nsp16 forming 7mGpppG2’Om-RNA.This 2’-O MTase activity is regulated by nsp10. To unravel the regulation of nsp10/nsp16 2’-O-MTase activity, we used purified MERS-CoV nsp16 and nsp10. First, we showed that nsp16 recruited N7-methylated capped RNA and SAM. The SAM binding promotes then the assembly of the enzymatically active nsp10/nsp16 complex that converted 7mGpppG (cap-0) into 7mGpppG2’Om (cap-1) RNA by 2’-OH methylation of N1 in a SAM-dependent manner. The subsequent release of SAH speeds up nsp10/nsp16 dissociation that stimulates the reaction turnover. Alanine mutagenesis and RNA binding assays allowed the identification of the nsp16 residues involved in RNA recognition forming the RNA binding groove (K46, K170, E203, D133, R38, Y47 and Y181) and the cap-0 binding site (Y30, Y132 and H174). In order to develop specific inhibitors blocking both enzymatic activities, we set up a robust enzymatic assay to screen chemical library. We first screened a chemical library containing 1200 compounds having the AMM (marketing authorization) and 320 natural compounds on both nsp14 N7 MTase and nsp16 2’-O-MTase activity, we have obtained 11 and 5 primary hits, respectively with inhibition percentage superior to 80%. In a second set of experiments we tried to identify compounds blocking the nsp10/nsp16 interaction by using the 2P2I3D library enriched in compounds (2000) that targeted the protein-protein interaction surface. We have obtained 68 with 50% inhibition and 122 with 40% inhibition. The IC50 of these compounds will be determined soon in order to select the best compounds for the hit to lead determination.

Wahiba Aouadi has done her Diploma of Higher Studies (DES) in Biochemistry in the year 2009 from University Mohamed Boudiaf - M'sila, Algeria. She obtained her Master’s in Development and Immunology from Aix-Marseille University (France) in the year 2013. Currently, she is doing her PhD from the AFMB Laboratory of Aix-Marseille University with Infectiopole Grant on the Characterization of the Middle East respiratory syndrome coronavirus (MERS-CoV) capping enzymes, a prerequisite for drug design. Recently, her work has been accepted for publication in Journal of Virology.

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version